GlassScriptPhysician profile
Gregory D Sketas
NPI 1710340088
$3,795.77
in general payments reported to CMS, 2019-2025
35 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $371 · 2021: $523 · 2022: $719 · 2023: $753 · 2024: $762 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,105.01 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Axsome Therapeutics, INC. | $259.84 | 2022-2025 | Auvelity |
| Pfizer INC. | $226.06 | 2020-2025 | |
| Glaxosmithkline, LLC. | $202.29 | 2020-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $201.30 | 2020-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.22 | 2019-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $155.82 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $142.74 | 2022 | |
| Novo Nordisk INC | $137.66 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lundbeck LLC | $126.79 | 2024-2025 | Rexulti |
| Allergan, INC. | $123.48 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $122.71 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $108.92 | 2019-2023 | Trintellix |
| Hologic Sales and Service, LLC | $99.15 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.53 | 2021-2024 | Caplyta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.88 | 2024-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $53.62 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $50.21 | 2023-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $37.25 | 2021 | |
| Vanda Pharmaceuticals INC. | $36.43 | 2024 | Fanapt, Hetlioz |
| Astellas Pharma US INC | $28.35 | 2025 | Veozah |
| Boston Scientific Corporation | $27.91 | 2025 | Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $26.55 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $25.38 | 2019 | |
| Alkermes, INC. | $25.14 | 2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $23.87 | 2023 | Austedo Xr |
| Sun Pharmaceutical Industries INC. | $22.72 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.23 | 2024 | Rexulti |
| Eisai INC. | $17.72 | 2020 | |
| Horizon Therapeutics Plc | $15.19 | 2021 | |
| Shield Therapeutics INC | $15.16 | 2024 | |
| Medtronic, INC. | $13.44 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.54 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.59 | 2019 | |
| Inogen, INC. | $6.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Sketas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.